Hetrombopag (SHR8735; Herombopag; Hengqu) is a novel, potent, orally bioavailable, and non-peptide thrombopoietin (TPO) receptor agonist developed by Jiangsu Hengrui Pharmaceutical for the treatment of thrombocytopenia and aplastic anaemia. In June 2021, hetrombopag gained the first approval in China as a second-line treatment for primary immune thrombocytopenia (ITP) and severe aplastic anaemia (SAA) in adults. Hetrombopag can be used to treat low platelet levels in people who have a certain blood disorder called chronic immune thrombocytopenia purpura or who have chronic hepatitis C. It may also be used to treat people with a certain blood disorder.

纯度：≥98%

CAS：1257792-41-8